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CMI and the ESCMID on the Global Scene of
Microbiology
At the request of the ECCMID, we have evaluated the balance
between various countries’ involvements with and contribu-
tions to CMI [1]. First of all, microbiology is one of the ﬁelds in
which Europe has produced more articles and generated more
citations in 10 years (80 000 articles between 1997 and 2008,
with 1.5 million citations [2]) than the USA (50 000 articles
between 1997 and 2008, with 1.2 million citations [2]). This is
one of the rare ﬁelds in which this trend can be clearly
observed. By means of ISI the Web of Knowledge, we gathered
the 40 ‘highly cited’ scientists in microbiology. Once we had
extended their number of citations to ‘all ﬁelds’ and removed all
synonyms, we obtained Table S1, which presents each author’s
number of citations and H index. This shows that, among the
40 most cited microbiologists, 19 are American, 15 are
European, and two are from other continents.
In Europe, the countries with the most publications are the
UK, Germany, France, Spain, and The Netherlands, followed
by Italy, Switzerland, Belgium, Sweden, and Denmark [2]; the
four most cited authors are French, German, British, and
Italian [2]. The majority of the articles published within the last
few years have essentially focused on genomics; the most cited
of all is an article by Stewart Cole on the genome of
Mycobacterium tuberculosis [3].
If we observe scientiﬁc production as a whole, it appears that
this is correlated with the gross domestic product (GDP)
(Fig. 1). An interesting point is raised by the comparison
between the increase in GDP and that in global publications
(Fig. 2). It seems clear that the countries whose scientiﬁc
production is developingmost rapidly are the same as those that
have been growing in termsof economyover these last 10 years.
Among the countries with a high GDP, those that are
progressing the most are those that are most open to
international students, such as Spain, Australia, or Canada—all
countries of immigrants. It seems that welcoming southern
students and investigators is a factor in the increase in scientiﬁc
production. In fact, a similar trend is observed in microbiology,
with a noteworthy increase in southern countries’ scientiﬁc
production (Fig. 3).
More directly related to CMI, the most proliﬁc contributors
are as follows: Spain, France, China, Italy, Taiwan, The Nether-
lands, the USA, Germany, and India; those that publish the most
are France, Spain, Italy, The Netherlands, Greece, China,
Germany, and India (Table 1). The national ratios of submission
per capita and those of acceptance are shown in Fig. 4. The
reasons why some countries have very little success were
analysed, and are shown in Table 2. The major reason for
rejection (for 27% of the manuscripts) is that the topic is too
locally focused, and thus might not concern the international
community; 23% of the submissions were rejected for scientiﬁc
reasons (e.g. not enough arguments, analysis lacking thorough-
ness, or contradictory or implausible results). Nineteen per cent
of the submissions were outside of the journal’s scope, 17%
focusing on non-priority subjects, and one review was rejected,
because CMI publishes only invited reviews. For the remaining
13%, the reasons could not be analysed, because the manuscripts’
ﬁles had been archived. The poor coverage of south-eastern
Europe and its neighbouring countries was partially addressed, as
a ﬁrst measure, by scheduling a thematic issue devoted to
research on infectious diseases in Iran, Egypt, and Turkey [4–7].
Besides this speciﬁc region, CMI continues to receive and
publish articles from all over the world (Tables 3 and S2).When
2012 ﬁgures were compared with statistics for the previous
year [8], the most noticeable change concerned Brazil, whose
acceptance rate grew by seven points; this gave it a very
reasonable acceptance rate, taking it out of the category of least
published countries. Also, Korea, Mexico, Croatia and Mada-
gascar have, respectively, published 12%, 20%, 22% and 100% of
their submissions, as compared with none in the previous year.
Several new countries have also submitted this year: Bangla-
desh, Central African Republic, Estonia, Indonesia, Malta,
Nigeria, and Uruguay. When we compared the sources of our
articles over these last 4 years with those of a broad spectrum
of journals of infectious diseases (Clinical Infectious Diseases,
Emerging Infectious Diseases, Journal of Infectious Diseases, and
Journal of Infection), it emerged that we publish signiﬁcantly more
articles from any European countries (including Turkey, and
excluding the UK, which publishes more in the Journal of
Infection) and also more articles from Israel, Lebanon, Egypt and
Tunisia than the investigated journals (Table S3).
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CMI with regard to international competition
CMI’s position with regard to international competition is
continuing to improve. Even though its 2011 impact factor
showed a slight drop as compared with 2010 (4.540 vs. 4.784),
this is still a very good score within a particular phase for the
journal. Indeed, this is attributable to the increased size of the
journal in 2010, a strategy that was adopted to clear up the
backlog of articles waiting to be published and reduce the
delays before publication (see ‘Production management’,
below). Nevertheless, the number of citations has increased
by 12.5%, which shows that CMI is more and more valued by
the scientiﬁc community.
Readership
After CMI articles were downloaded 619 507 times in 2011
(+61% as compared with 2010), with an average of 50 000
downloads per month, 2012 has started with 58 000 in
January. The online usage is regularly growing: on 15 Septem-
ber, it had reached 527 621 downloads, i.e. approximately
62 000 per month, so it is already 20% more than last year.
Editorial Trends
Editorial board
While analysing the geographical origins of the CMI editorial
board (Fig. S1), we noticed that Germany and Turkey were
under-represented in proportion to their populations. In
order to ﬁx these gaps, four members were recruited in the
Scientiﬁc Committee, two from each country (respectively,
Oliver A. Cornely and Petra Gastmeier, and Sevtap
Arikan-Akdagli and Onder Ergonul). These members
were also chosen in order to reinforce two sections that
were growing, and consequently required more experts:
(a)
(b)
Gross domestic product (GDP) per capita in
201028
Number of publications per capita (2007–2011)
>$102 400
$51 200 – $102 400
$25 600 – $51 200
$12 800 – $25 600
$6 400 – $12 800
$3 200 – $6 400
$1 600 – $3 200
$800 – $1 600
$400 – $800
<$400
Negligible
No data available
>1 × 10–6
>100 × 10–6
>500 × 10–6
>2500 × 10–6
FIG. 1. Wealth and scientiﬁc production currently go together. The map (a) extracted from Wikipedia (February 2012), shows the gross domestic
product (GDP) per capita, the usual way to measure the wealth of states. The map (b) presents what can be called the current state of ‘science domestic
production’ per capita. Using the same principle as the GDP, this was calculated by gathering, for each country, the number of scientiﬁc publications,
including all ﬁelds, over the previous 5 years (2007–2011) and calculating a ratiowith the number of inhabitants. This results in the numberof publications
per capita.
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(a)
(b)
>10
GDP growth rate
>5
>1
<0
>0
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No data available
No data available
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>15%
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FIG. 2. Growing rates of gross domestic product (GDP) and scientiﬁc production also go together. (a) Made by calculating the real GDP growth
rate over the previous year (2011). (b) Made by calculating the growth rate of scientiﬁc production in ‘all ﬁelds’ between 2001 and 2011.
(a)
(b)
>100 × 10–6
Publications in microbiology:
Number per capita
Growth rate
>50 × 10–6
>10 × 10–6
>1 × 10–6
No data available
No data available
>75%
>35%
>15%
<0
>15%
FIG. 3. The rate of evolution scientiﬁc production in microbiology. (a) The number of publications per capita in microbiology over the last 5 years
(2007–2011). (b) The growing rate of publications in microbiology between 2001 and 2011.
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Epidemiology and Mycology. A Swedish expert in mycology,
Lena Klingspor, was also hired, completing this section, which
now includes four experts, as compared with one in 2011. In
addition, an expert in prosthetics infections, Werner Zimm-
erli, also joined the board, as these are becoming a major issue
in the journal. Concurrently, some members who had been
working for CMI for more than 3 years voluntarily left the
board. In this way, CMI ensures that its editorial board is
adapted to its evolving scope and remains dynamic through
regular renewals.
Topical coverage
Clinical virology, mycology and tropical and parasitic diseases
continure to expand within the scope of CMI publications. This
is because of the increase in the number of submissions in
these domains, subsequent to the growing interest in them
within the CMI editorial team, the ESCMID, and the scientiﬁc
community in general. Otherwise, CMI preserves a balance
between the other domains (bacteriology, epidemiology, and
infectious diseases).
The most cited and most downloaded articles in 2012 show
that CMI remains a reference for resistance to antibiotics and the
explorationof techniques, and is also attracting a growing interest
in virology (Tables S4 [9–18] and S5 [19–28]; from reference 21
see Supporting information: Bibliography references).
TABLE 1. The countries with the most submissions and
publications in CMI in 2011
Country of
submitting
author
Number of
submissions
Country of
submitting
author
Number of
accepted
manuscripts
Spain 124 France 22
France 102 Spain 21
China 70 Italy 16
Italy 69 The Netherlands 16
Taiwan 53 Greece 9
The Netherlands 52 China 8
USA 45 Germany 8
Germany 36 India 7
India 36 USA 7
UK 33 Denmark 6
(a)
(b)
<0.1 × 10–6
More than 40%
Between 20% and
40%
Between 1% and 20%
0%
>10 × 10–6
5 × 10–6 > × > 10 × 10–6
1 × 10–6 > × > 5 × 10–6
0.5 × 10–6 > × > 1 × 10–6
0.1 × 10–6 > × > 0.5 × 10–6
FIG. 4. The geographical distribution of CMI submissions and publications between 2010 and June 2012. (a) The national submission ratios per
capita. (b) The national acceptance rates.
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Editorial content
Each CMI monthly issue continues to focus on one key topic.
The 2012 schedule shows that we are keeping CMI’s historical
focuses, such as resistance to antibiotics, and at the same time
opening up to disciplines of growing interest for CMI and the
scientiﬁc community, such as advances in virology, infectious
diseases, parasitology, and epidemiology, as well as the growing
signiﬁcance of countries emerging on the global scene of
science (see Supporting information: Table S6 and Bibliography
references 29–83). In 2013, several issues will be dedicated to
new ﬁelds, and some controversial topics (such as infectious
cases of obesity, bacteraemia, pig-related infections, and
controversies on predictions regarding infectious diseases);
also, virology and parasitology will be given a place of honour,
with topics such as the analysis of the available detection
resources in tropical countries and the spread of mosquito-
transmitted diseases (Table S6). In addition to the variety and
the scientiﬁc interest of these topics, the CMI team is proud to
display, each month, front covers that are carefully designed to
fulﬁl both science requirements and aesthetic tastes. We hope
that readers appreciate this.
CMI Infection Hot Topics
We have continued to appeal to staff and guests for feedback
and reactions on current topics. In 2012, we have published
reactions on the ancient plague (see Supporting information:
Bibliography reference 84], Staphylococcus aureus endocarditis
(see Supporting information: Bibliography reference 85), anti-
biotic resistance (see Supporting information: Bibliography
reference 86), the relationship between soldiers and epidem-
ics (see Supporting information: Bibliography reference 87),
the use of interferon-gamma release assays (see Supporting
information: Bibliography reference 88), and ‘culturomics’ as a
new approach to studying the human microbiome (see
Supporting information: Bibliography reference 89).
Production Management
Turn-around
The number of submissions continues to increase regularly
(+27% since 2008), while the acceptance and rejection rates
remain stable (17% acceptance; 83% rejection). These rates
reﬂect CMI selection policy, based on high quality, and ﬁt the
publication requirements.
Backlog management
A few years ago, many papers were waiting to be published
(backlog), which implied very long publication delays. There-
fore, over the years, several measures were implemented in
order to take these delays down to a reasonable level. In
2010 and 2011, the size of the journal was increased, with
668 articles being published, i.e. 67% extra copy. The copy
backlog was divided by three, and the delay between ﬁnal
acceptance and print publication has been stable, at 4 months,
since November 2011. In 2012, the CMI paper edition has
returned to its original size (100 pages). In order to meet
both volume and quality requirements, we decided to publish
a part of the journal online only. Since August 2011, all
Research Notes have been switched to e-format, with their
abstracts published in the print issues; and in January 2012, all
justiﬁed oversized Original Articles (exceeding 2500 words)
TABLE 3. The 20 countries with the most submissions, with
their acceptance rates (January 2010 to 11 September 2012)
Country
Submitted
papers
Accepted
papers
Acceptance
ratio (%)
Rejected
papers
Rejection
ratio (%)
Spain 339 82 24.19 257 75.81
France 332 134 40.36 198 59.64
China 229 24 10.48 205 89.52
Italy 220 68 30.91 152 69.09
Taiwan 171 26 15.20 145 84.80
The
Netherlands
149 45 30.20 104 69.80
USA 145 38 26.21 107 73.79
Germany 117 38 32.48 79 67.52
India 105 12 11.43 93 88.57
UK 94 32 34.04 62 65.96
Greece 91 35 38.46 56 61.54
Switzerland 82 37 45.12 45 54.88
Brazil 80 8 10.00 72 90.00
Turkey 76 4 5.26 72 94.74
Republic
of Korea
66 8 12.12 58 87.88
Denmark 54 22 40.74 32 59.26
Japan 54 9 16.67 45 83.33
Sweden 51 13 25.49 38 74.51
Australia 49 17 34.69 32 65.31
Israel 46 20 43.48 26 56.52
TABLE 2. Why are some so low?
Number of papers
accepted/submitted Out of scope Science
Unsolicited
Review
Locally
limited
Not a
priority
Files archived or
reason undeﬁned
Brazil 1/28 9 4 1 5 1 7
Egypt 0/7 1 2 0 3 0 1
Iran 0/20 2 6 0 7 2 3
Turkey 1/29 3 6 0 5 13 1
Pakistan 0/11 3 3 0 5 0 0
Total 2/93 18 21 1 25 16 12
235 19% 23% 1% 27% 17% 13%
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joined those. This means that more articles can be published
with shorter delays. The e-format has exactly the same
citation rate and accessibility, so the authors are not
penalized. Also, another advantage of the new policy is that
e-articles do not wait before publication: these are displayed
online in their unedited version, as are all CMI articles,
1 week after acceptance, and then 3–5 weeks later in their
copy-edited version, and their abstracts are immediately
allocated to the next print issue. In the ﬁrst nine issues of
2012, 79 online-only articles were published, representing
376 pages that would have otherwise been added to the
backlog and have waited before publication. The resized
journal thus now includes a themed section (an editorial and
three to ﬁve invited reviews), ten Original Articles, and the
abstracts of online-only papers. With this new policy, the
backlog is naturally decreasing.
Processing time
The processing time for the management of the manuscripts
has continued to improve since 2009. In 2012, this averaged
18.5 days, i.e. less than half of the 2009 ﬁgure (40 days). This is
based on an average of 7 days for immediate rejection, and
30 days for a ﬁrst decision after peer-review (acceptance,
rejection, or revision).
Conﬂict of interest policy
In order to conform to the most rigorous standards of
transparency, preserve public trust in the peer-review process,
and the credibility of the publication as a whole, CMI has
updated its transparency declaration form. We now request a
full statement as established by the International Committee of
Medical Journal Editors (ICMJE).
Conclusion and Perspectives
Through its interest in both growing and more established
disciplines, its attention to communicating discoveries from all
over the world, and its willingness to cover current or even
potentially controversial topics, CMI suits, all at the same time,
the ﬁelds of activities of the ESCMID, which owns the
publication, frontline science, and also, as both a result and a
choice, the geopolitical evolution of the global scene of
science.
By continuing to adapt its publication scope to current
issues and improving the practical context for contributors (in
terms of delays, transparency, and fairness of the peer-review),
CMI aims to maintain a high standard of publication, in order
to provide the scientiﬁc community with cutting-edge research
results and analysis.
Transparency Declaration
No conﬂict of interest is declared.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Geographical distribution of the CMI editorial
board.
Table S1. The 40 ‘highly cited’ in microbiology.
Table S2. Submissions and acceptances per country
(January 2010 to 11 September 2012).
Table S3. Comparison of the geographical origins of CMI
submissions and publications with other journals’ production.
Table S4. Ten most cited papers in 2012.
Table S5. Ten most downloaded papers in 2012.
Table S6. Themed sections published in 2012 and sched-
uled for 2013.
Data S1. Bibliography [21–89].
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